Skip To Main Content
Barrett R.B. Nuttall on Muck Rack

Barrett R.B. Nuttall

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barrett R.B.

Contact Barrett R.B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo - Nature Communications

|
By Burcu Bestas, Sandra Wimberger, Alexandra Madsen, Antje K. Rottner, Songyuan Li, Barrett R.B. Nuttall, Grzegorz Sienski, Niklas Selfjord, Elke Ericson, Amir Taheri-Ghahfarokhi
| Nature Verified
Abstract Streptococcus pyogenes Cas9 (SpCas9) and derived enzymes are widely used as genome editors, but their promiscuous nuclease activity often induces undesired mutations and chromosomal rearrangements. Several strategies for mapping off-target effects have emerged, but they suffer from limited sensitivity. To increase the detection sensitivity, we develop an off-target assessment workflow that uses Duplex Sequencing.
Open in Who Shared Issue with article?

Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance

|
By Daniel B Stetson, Ambar Ahmed, Xing Xu, Barrett R.B. Nuttall
| ascopubs.org
Increased reliance on liquid biopsy specimens for oncologic clinical decisions emphasizes the critical need for sensitive, specific multigene tests to detect genetic aberrations.
Open in Who Shared Issue with article?

Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance

|
By Daniel B Stetson, Xing Xu, Ambar Ahmed, Barrett R.B. Nuttall
| ascopubs.org
Discordance between plasma and tumor variant calling has been attributed primarily to tumor heterogeneity, whereas technical variables remain largely unexplored. To measure these variables, we tested four next-generation sequencing (NGS) gene panel assays for mutations in circulating tumor DNA (ctDNA) using replicate sets of 24 plasma samples and compared the results with matched tumor-normal tissue pairs.
Open in Who Shared Issue with article?
See all 3 articles